ALRN To Report Data In Q4, IMUC Hits New High, VYGR Pulls Out Of ABBV Deal, VNDA To Face FDA In Dec.

Today's Daily Dose brings you news about the progress in Aileron's phase Ib clinical study of ALRN-6924, CymaBay's positive results from ENHANCE study, FDA approval of GW Pharma's Epidiolex for a new indication, Immunic's multiple sclerosis trial results, Rhythm Pharma's anticipated milestones, and the progress in the trial conducted by COVID R&D Alliance.

from RTT - Biotech https://ift.tt/33kTIU5
via IFTTT